JTP3309, a newly synthesized lipid A-subunit analogue, was examined for in vitro andin vivo antimycobacterial activities. Firstly, the effect of JTP3309 on the in vitro antimycobacterial activity of murine peritoneal macrophages (Mos) was studied. When residentperitoneal MOs from CBA mice which had phagocytosed Mycobacterium avium were treated with JTP3309 once from 0 hr to 24hr after the initiation of MOs cultivation or three timesfrom 0 hr to 24hr, 48hr to 72hr and 96hr to 120hr of culture period, there was no increasein the anti-M. avium activity of the treated MOs. On the other hand, the bacterial growthwas slightly inhibited in peritoneal MOs from mice which had been injected with JTP 3309, in comparison with that seen in resident MOs. Secondly, protective and therapeuticefficacies of JTP3309 against
M. avium and
M. fortuitum infections in mice were studied, based on the suppression of the bacterial growth in the visceral organs including the lungs, kidneys and spleen. BALB/c mice infected i. v. with
M. avium were given JTP3309 i. v. at thedoses of 10 and 20μg/mouse according to the following protocols; protocol A, twoinjections 4 and 1 day (s) before the infection; protocol B, once daily at days 1, 3, 5, 12, 19, 26, 33, 40, 47 and 54 after the infection; protocol C, once daily at days 1, 8, 15, 22, 29, 36, 43 and 50 after the infection. Only protocol A could reduce the number of CFU recoveredfrom the spleen of infected mice. A/J mice infected i. v. with
M. fortuitum were givenJTP3309 i. v. at doses of 10 and 20-Eg/mouse, in the same administration schedules as aboveexcept for mice killed on day 28. Only mice given JTP3309 in the protocol A were protectedfrom the death and the number of CFU recovered from their spleen on day 28 weresignificantly reduced. These results show that JTP3309 possesses protective but nottherapeutic activity against
M. avium or
M. fortuitum infection.
抄録全体を表示